Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 681323; GSK 681323; SB 681323

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Analgesics; Anti-inflammatories; Antibronchitics; Antirheumatics; Pyrimidines; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Atherosclerosis; Chronic obstructive pulmonary disease; Neuropathic pain; Rheumatoid arthritis

Most Recent Events

  • 16 Sep 2009 Efficacy, adverse event and pharmacodynamics data from a phase II trial in Chronic obstuctive pulmonary disease presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
  • 06 Dec 2005 Phase-II clinical trials in Atherosclerosis in the UK
  • 30 Nov 2005 Phase-II clinical trials in Rheumatoid arthritis (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top